article · BMC Infectious Diseases
BACKGROUND: Multidrug resistant Mycobacterium tuberculosis (MDR-TB) is the main public health problem in resource constrained settings particularly in the Tigray region of Ethiopia, where diagnostic and treatment service are limited. Therefore, we aimed to examine post-war prevalence of MDR-TB in Tigray region. METHODS: A cross-sectional study was conducted in Tigray Region between February 2024 and January 2025. 163 GeneXpert tested positive sputum samples were collected, transported and processed for acid-fast bacilli staining, culture and drug susceptibility testing. The 106 (65%) MTBC samples culture positive isolates were subjected to drug susceptibility test using 1st- and 2nd- line anti-TB drugs using molecular line probe assay. Descriptive statistics, binary and multivariable logistic regression were done. A statistical test was regarded as significant when the P value was ˂0.05. RESULT: MDR-TB was detected at the rate of 18.9. Patients who smoke cigarettes (AOR = 15.64, 95% CI = 3.05580.126) were 15.64 times more likely to develop MDR-TB than those who did not smoke. HIV positive patients (AOR = 5.31, 95%CI 1.305-21.615) were 5.31times more than to develop MDR-TB than those who did not have HIV. Single TB patients were less likely to develop MDRTB compared to married and divorced TB patients. CONCLUSION: The prevalence of Multidrug-Resistant Tuberculosis (MDR-TB) was high in Tigray region, especially in previously treated TB cases. This warrants urgent public health intervention to prevent the transmission of MDR-TB in the community.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s12879-026-13660-5
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.